EU Trials Register Now Holds Data on Over 50k Studies
Information about more than 50,000 clinical trials is now available on the European Union (EU) Clinical Trials Register.
The register contains data on 31,456 current trials with a EudraCT protocol, of which 5,048 are clinical trials conducted on subjects of less than 18 years of age. It also presents details about 18,700 older pediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
The register, which covers studies that started after May 1, 2004 allows users to search for protocol and results information on both interventional clinical trials that are conducted in the EU and the European Economic Area (EEA), as well as clinical trials conducted outside the EU/EEA that are linked to European pediatric medicine development.
It also maintains a list of patient/consumer organizations who may be able provide information on clinical trials within various disease areas. These are organizations that regularly work with the European Medicines Agency.
For more information about the initiative, click here.
Philip Ward is the European Editor for Applied Clinical Trials.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
July 9th 2025In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent safety profile in patients with symptomatic TGCT not amenable to surgery.
